EP3325005A4 - Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie - Google Patents

Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie Download PDF

Info

Publication number
EP3325005A4
EP3325005A4 EP16828158.2A EP16828158A EP3325005A4 EP 3325005 A4 EP3325005 A4 EP 3325005A4 EP 16828158 A EP16828158 A EP 16828158A EP 3325005 A4 EP3325005 A4 EP 3325005A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
peptides
identification
major histocompatibility
histocompatibility complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16828158.2A
Other languages
German (de)
English (en)
Other versions
EP3325005A1 (fr
Inventor
Brian J. Czerniecki
Gary K. Koski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/041034 external-priority patent/WO2016011432A2/fr
Application filed by Individual filed Critical Individual
Publication of EP3325005A1 publication Critical patent/EP3325005A1/fr
Publication of EP3325005A4 publication Critical patent/EP3325005A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
EP16828158.2A 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie Withdrawn EP3325005A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2015/041034 WO2016011432A2 (fr) 2014-07-17 2015-07-17 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
PCT/US2016/021042 WO2017014810A1 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Publications (2)

Publication Number Publication Date
EP3325005A1 EP3325005A1 (fr) 2018-05-30
EP3325005A4 true EP3325005A4 (fr) 2019-03-27

Family

ID=57835029

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16828158.2A Withdrawn EP3325005A4 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
EP16828163.2A Withdrawn EP3324990A4 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16828163.2A Withdrawn EP3324990A4 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Country Status (5)

Country Link
EP (2) EP3325005A4 (fr)
JP (3) JP2018527286A (fr)
CN (1) CN107206045A (fr)
CA (2) CA2992925A1 (fr)
WO (2) WO2017014810A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325005A4 (fr) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
WO2021051066A1 (fr) * 2019-09-13 2021-03-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Thérapie par dc1 pulsées avec her3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008214A1 (fr) * 1989-12-01 1991-06-13 The United States Of America, Represented By The Secretary, United States Department Of Commerce Segment adn codant un gene pour un recepteur apparente au recepteur du facteur de croissance epidermique

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
EP2258712A3 (fr) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
EP2400021B1 (fr) * 2002-03-26 2016-11-30 Zensun (Shanghai) Science & Technology, Co., Ltd. Procédés de type ErbB3 et compositions pour traiter des tumeurs malignes
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007115571A2 (fr) * 2006-04-07 2007-10-18 Enkam Pharmaceuticals A/S Fragments peptidiques dérivés du récepteur erbb
AU2007258874B2 (en) * 2006-06-15 2013-11-14 Seqirus UK Limited Adjuvant-sparing multi-dose influenza vaccination regimen
CN102326081B (zh) * 2009-02-24 2014-11-19 霍夫曼-拉罗奇有限公司 s-ErbB-3作为癌症标志物的应用
JP2010200693A (ja) * 2009-03-04 2010-09-16 Chiyoda Kako Kensetsu Kk 樹状細胞ワクチン製造用培養装置並びに樹状細胞の製造方法
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
EP2461828B1 (fr) * 2009-07-31 2017-06-21 President and Fellows of Harvard College Programmation de cellules à des fins de thérapie tolérogénique
CN102933228A (zh) * 2010-03-15 2013-02-13 宾夕法尼亚大学董事会 制备和储存活化的、成熟树突细胞的体系和方法
KR102101806B1 (ko) * 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
AU2012349735B2 (en) * 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201601754A (zh) * 2013-09-30 2016-01-16 第一三共股份有限公司 核酸生物標記及其用途
EP3169354A4 (fr) * 2014-07-17 2018-06-13 Brian J. Czerniecki Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
EP3325005A4 (fr) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008214A1 (fr) * 1989-12-01 1991-06-13 The United States Of America, Represented By The Secretary, United States Department Of Commerce Segment adn codant un gene pour un recepteur apparente au recepteur du facteur de croissance epidermique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUNFA PENG ET AL: "Alterations in Barrett's-related adenocarcinomas: A proteomic approach", INTERNATIONAL JOURNAL OF CANCER, vol. 122, no. 6, 15 March 2008 (2008-03-15), pages 1303 - 1310, XP055178816, ISSN: 0020-7136, DOI: 10.1002/ijc.23258 *
See also references of WO2017014810A1 *

Also Published As

Publication number Publication date
EP3324990A4 (fr) 2019-04-03
CN107206045A (zh) 2017-09-26
EP3324990A1 (fr) 2018-05-30
EP3325005A1 (fr) 2018-05-30
JP2018521953A (ja) 2018-08-09
JP2021043204A (ja) 2021-03-18
WO2017014816A1 (fr) 2017-01-26
WO2017014810A1 (fr) 2017-01-26
CA2992925A1 (fr) 2017-01-26
CA2992937A1 (fr) 2017-01-26
JP2018527286A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
IL285403A (en) Mhc class i epitope delivering polypeptides
EP3383418A4 (fr) Peptides slc45a2 pour l'immunothérapie
EP3423044A4 (fr) Nanovaccin activant sting pour l'immunothérapie
IL263896A (en) T cell compositions for immunotherapy
IL256922A (en) Pd-l1 (" programmed death-ligand 1" ) antibodies
EP3347026A4 (fr) Modification génétique de macrophages pour l'immunothérapie
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
EP3493827A4 (fr) Compositions et procédés pour immunothérapie
EP3373970A4 (fr) Protéine de fusion nkg2d-ig pour l'immunothérapie contre le cancer
EP3645569A4 (fr) Immunothérapie pour carcinome hépatocellulaire
EP3390429A4 (fr) Protéines capsidiques modifiées pour la libération améliorée de vecteurs parvoviraux
EP3402517A4 (fr) Immunothérapie du cancer
EP3458756A4 (fr) Adaptateur de bride
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
GB201511191D0 (en) T-cell epitopes for the immunotherapy of myeloma
EP3294165A4 (fr) Procédés pour l'implantation d'une vis à os
EP3419674A4 (fr) Immunothérapie de ciblage de l'amyloïdose
MA41433A (fr) Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
DK2968485T3 (da) Peptidvaccine til forebyggelse og immunterapi af demens af Alzheimers-typen
HUE058257T2 (hu) Eljárások oxatiazin-jellegû vegyületek elõállítására
EP3291722A4 (fr) Réfracteur d'objectif amélioré
FR3017658B1 (fr) Boitier d'entrainement d'equipements pour turbomachine
EP3347098A4 (fr) Ciblage de l'activation de mda-5 pour l'immunothérapie du cancer
FR3056552B1 (fr) Harpon d'ancrage externe pour aeronef
EP3463420A4 (fr) Peptides pour la croissance des cheveux

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190221

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/574 20060101AFI20190215BHEP

Ipc: C07K 14/71 20060101ALI20190215BHEP

Ipc: A61K 39/00 20060101ALI20190215BHEP

Ipc: A61P 35/00 20060101ALI20190215BHEP

Ipc: C12N 5/0783 20100101ALI20190215BHEP

Ipc: C12N 5/0784 20100101ALI20190215BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190924